REGENXBIO Inc — Cash Flow (NASDAQ:RGNX) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Cash from operating activities -54.06 M218.88 M-207.49 M-218.41 M-173.13 M-123.96 M -123.96 M Cash from investing activities 122.76 M-406.64 M-11.93 M190.94 M103.45 M-15.87 M -15.87 M Cash from financing activities 200.21 M195.25 M-28.84 M-34.97 M92.68 M116.77 M 116.77 M Free cash flow -80.93 M134.7 M-238.21 M-228.37 M-175.56 M-126.38 M -126.38 M

Haberler

Denali Jumps, Pulling Regenxbio Higher, On Early FDA Approval

Regenxbio, GlaxoSmithKline ile 10 milyon dolarlık anlaşma

OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development

Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data

OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch

Regenxbio CMO Pakola 53 bin dolarlık RGNX hissesi sattı

Pakola Steve, Regenxbio CMO, sells $53k in RGNX stock

REGENXBIO Inc. (RGNX) Presents at 2026 MDA Clinical & Scientific Conference - Slideshow (NASDAQ:RGNX) 2026-03-12

Stifel, Duchenne denemesi verilerine dayanarak Regenxbio hisse notunu korudu

Stifel reiterates Regenxbio stock rating on Duchenne trial data

Regenxbio, Duchenne gen tedavisi için olumlu veri açıkladı

Regenxbio reports positive interim data for Duchenne gene therapy